Paclitaxel-coated balloons compared to drug-eluting stents in the treatment of narrowed blood vessels of the heart
Résumé de l'étude
The SPARX STUDY was designed for patients suffering from ischemic heart disease – a condition where there is an imbalance between the oxygen supply and demand of the heart muscle. The two subtypes of this disease are the focus of this study: chronic coronary syndromes (CCS) and acute coronary syndrome without ST-segment elevation (NST-ACS). The aim is to compare different medical devices routinely used in hospitals for the treatment of patients with CCS and NST-ACS. The SPARX study was developed to compare two DCBs (Protégé™ and Agent™) with standard DES in complex and small coronary lesions. The idea behind it is that paclitaxel-coated balloons work as well as modern drug-eluting stents. The study also compares Protégé and Agent, two well-known drug-eluting balloons. The main hypothesis states that Protégé™ works at least as well as Agent™. In this study, participants are randomly assigned to three groups. This is called randomization. Each group receives treatment with a different medical product - drug-eluting stents or the drug-eluting balloon Protégé or the drug-eluting balloon Agent. Regardless of which group patients are assigned to, they receive a standard treatment that is also applied to all other patients with the same condition. SPRAX is a so-called open study. This means that both the doctor and the patient know which group they have been assigned to and which treatment they have received. A total of 1380 patients are expected to participate in this clinical study across approximately 30 hospitals in several countries such as Switzerland, Germany, France, Italy, Austria, the Netherlands, and India. Each patient's participation in this clinical study is expected to last up to 24 months.
(BASEC)
Intervention étudiée
The intervention being studied is a percutaneous coronary intervention (PCI), where either balloon angioplasty is performed with a drug-eluting balloon that delivers and releases a drug evenly to the vessel wall, or a drug-eluting stent (DES) is implanted. Regardless of which group patients are assigned to, they receive a standard treatment that is also applied to all other patients with the same condition.
(BASEC)
Maladie en cours d'investigation
The disease under investigation is ischemic heart disease – a condition where there is an imbalance between the oxygen supply and demand of the heart muscle. The two subtypes of this disease are the focus of this study: chronic coronary syndromes (CCS) and acute coronary syndrome without ST-segment elevation (NST-ACS).
(BASEC)
1. Age ≥18 years 2. Patients with NSTE-ACS or CCS with either symptoms and/or ischemia on non-invasive or invasive tests (i.e., FFR/iFR, CMR, SPECT, PET-CT, or stress echo) 3. The patient must be able to understand and provide written informed consent and comply with all study procedures (BASEC)
Critères d'exclusion
1. STEMI or cardiogenic shock related to an acute MI within 2 days prior to the index PCI 2. Pregnancy or breastfeeding certificate (according to country-specific guidelines) (a negative pregnancy test is required within 7 days prior to enrollment for women of childbearing age) 3. LVEF<30% (BASEC)
Lieu de l’étude
Luzern
(BASEC)
Sponsor
Sponsor: Blue Medical Devices B.V., A Translumina Group Company Swiss Representative: Effectum Medical
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
PD Dr. med. Matthias Bossard
+41 412051477
matthias.bossard@clutterluks.chLuzerner Kantonsspital - Heart Center
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
07.04.2026
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Stents versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible